HC Wainwright set a $14.00 target price on Capricor Therapeutics Inc (OTCMKTS:CAPR) in a research report released on Thursday morning. The firm currently has a buy rating on the stock.

A number of other research firms have also recently weighed in on CAPR. Rodman & Renshaw started coverage on shares of Capricor Therapeutics in a report on Monday, February 13th. They issued a buy rating and a $14.00 price objective for the company. Zacks Investment Research cut shares of Capricor Therapeutics from a hold rating to a sell rating in a report on Friday, December 9th.

Shares of Capricor Therapeutics (OTCMKTS:CAPR) opened at 3.10 on Thursday. The firm’s 50-day moving average price is $2.78 and its 200 day moving average price is $2.98. The firm’s market cap is $66.34 million. Capricor Therapeutics has a 12-month low of $2.01 and a 12-month high of $5.40.

Capricor Therapeutics (OTCMKTS:CAPR) last issued its earnings results on Wednesday, March 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.16. On average, equities analysts expect that Capricor Therapeutics will post ($0.74) earnings per share for the current fiscal year.

Your IP Address:

A hedge fund recently raised its stake in Capricor Therapeutics stock. LLBH Private Wealth Management LLC increased its stake in shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) by 4.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 124,591 shares of the company’s stock after buying an additional 5,000 shares during the period. LLBH Private Wealth Management LLC owned 0.69% of Capricor Therapeutics worth $404,000 as of its most recent SEC filing.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Receive News & Stock Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related stocks with our FREE daily email newsletter.